PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 8, 2025Blood0 citationsOpen Access

Designing immune-evasive ucar-T cells for off-the-shelf immunotherapy

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYanan YueXBXiangji BianXSXiao‐Yu Song

Discussion

Loading...

Member takes

Overview

Engineered ucar-T cells demonstrate enhanced antitumor activity and reduced immune rejection, indicating potential for immunotherapy.

Key Points

  • To develop immune-evasive ucar-T cells that overcome allogeneic barriers and improve immunotherapy.
  • Developed three distinct UCAR-T cell products with different hypo-immunity strategies.
  • Evaluated each product's resistance to NK cell-mediated rejection and T cell-mediated rejection.
  • Conducted relevant assays including mixed lymphocyte reaction and examined antitumor activity in xenograft models.
  • Strategy 3 UCAR-T cells showed enhanced survival against NK cells compared to Strategy 1.
  • Strategy 2 effectiveness was dependent on HLA-C/KIR compatibility with strong allogeneic activation.
  • All UCAR-T products exhibited comparable antitumor activity; no treatment-related toxicities were noted in safety studies.

Cite This Study

Yue et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d462https://doi.org/10.1182/blood-2025-1045
View Full Paper
Ask AI
Bookmark
Share